BioPorto A/S (CPH: BIOPOR), a company specializing in in vitro diagnostics, has officially announced that Neil Goldman has communicated his decision to step down from his current position. Neil Goldman is resigning to assume the role of Chief Financial Officer at another company.
The company has initiated the search for a suitable successor to fill the CFO position, and Neil Goldman will actively participate in facilitating a smooth transition during the interim period, with the exact date to be determined.
Tony Pare, Chief Executive Officer of BioPorto, expressed his appreciation for Neil Goldman’s contributions during their nearly two-year partnership at BioPorto. Pare acknowledged the valuable impact Goldman has had across the company and conveyed his understanding of Goldman’s desire to explore new opportunities outside of BioPorto. He extended best wishes for Goldman’s future endeavors.
Neil Goldman shared his thoughts, saying, “BioPorto has a great team, and it has been a true privilege to be part of it. Together, we have brought focus and significant progress in addressing the unmet clinical need of identifying and treating patients at risk for Acute Kidney Injury. I take this opportunity to wish BioPorto and its talented people the very best for the future.”
Have you read?
The World’s Top 10 Highest-Paid Wealth Management Executives.
CEO compensation: Highest paid chief executive officers in the United States in 2022.
Highly-Paid Entertainment Chief Executives (Averaged $31.66 Million), 2022.
Highest paid health insurance CEOs.
Most Powerful Companies in Australia, 2023.
Add CEOWORLD magazine to your Google News feed.
Follow CEOWORLD magazine headlines on: Google News, LinkedIn, Twitter, and Facebook.
Copyright 2024 The CEOWORLD magazine. All rights reserved. This material (and any extract from it) must not be copied, redistributed or placed on any website, without CEOWORLD magazine' prior written consent. For media queries, please contact: info@ceoworld.biz
